Sorrento to Host Webcast on Empowering the Lymphatics

Overview

ATLANTA and SAN DIEGO, Nov. 13, 2022 (GLOBE NEWSWIRE) — Sofusa®, a wholly-owned division of Sorrento Therapeutics (Nasdaq: SRNE, “Sorrento”), today announced that it will host a virtual Key Opinion Leader (KOL) panel discussion titled “Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System” to be held on Thursday, November 17.

Event Details

The panel discussion will focus on the advancements in biologics targeting the immune system and how they can improve therapeutic outcomes for patients. Sorrento Therapeutics will be presenting newly presented clinical data demonstrating significant improvements in therapeutic results.

Implications

This event will shed light on the latest developments in immunotherapy and how biologics can specifically target the lymphatics to enhance immune system function. The discussion will explore the potential of these advancements to revolutionize the treatment of various diseases.

Impact on Individuals

For individuals, the webcast offers valuable insights into groundbreaking therapies that may improve their health outcomes. By understanding the advancements in biologics targeting the immune system, individuals can gain knowledge about potential treatment options for various conditions.

Impact on the World

On a global scale, the discussion on empowering the lymphatics through biologics represents a significant step forward in medical innovation. The potential for improved therapeutic outcomes and the ability to target specific areas of the immune system could have far-reaching implications for healthcare worldwide.

Conclusion

Overall, Sorrento’s upcoming webcast on empowering the lymphatics through biologics is a crucial event in the field of immunotherapy. By discussing the potential of targeting the immune system to enhance therapeutic benefits, this panel aims to drive innovation and improve treatment options for patients globally.